Trial Profile
A Randomised, Double-Blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination With 5-Fluorouracil, Leucovorin [folinic-acid], and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON-III
- Sponsors AstraZeneca; AstraZeneca AB
- 21 Jan 2023 Results of retrospective exploratory analysis were presented at the 2023 Gastrointestinal Cancers Symposium.
- 25 Jan 2020 Results assessing the patterns of opioid use, and evaluating the impact of opioid use on survival outcomes among patients with advanced GI cancers who were included in eight clinical trials (NCT01124786; NCT00844649; NCT00290966; NCT00678535; NCT00699374; NCT00272051; NCT00305188; NCT00384176) presented at the 2020 Gastrointestinal Cancers Symposium
- 23 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.